Stereotactic Body Radiation Therapy (SBRT) with Concomitant Chemotherapy (Campto) For Lung and Liver Metastases of ColoRectal Cancer (CRC): Preliminary Results of a Prospective Phase II Multicenter Study

Almaghrabi, M.Y.; Río, E. Del; Mahé, M.‐A.; Mirabel, X.; Martel, I.; Vendrely, V.; Carry, C.

doi:10.1016/j.ijrobp.2011.06.575

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 2007, we initiated a Phase II prospective multicentre study of SBRT and concurrent irinotecan in colorectal cancer patients with unresectable liver and lung metastases. As preliminary results for the combination did not differ significantly from those for SBRT alone, we increased the tumoricidal dose in order to achieve higher LC [ 68 ]. The study is ongoing.…”

Section: Introductionmentioning

confidence: 99%

Stereotactic body radiation therapy for abdominal oligometastases: a biological and clinical review

Almaghrabi¹,

Supiot

Pâris

et al. 2012

Radiat Oncol

View full text Add to dashboard Cite

Advances in imaging and biological targeting have led to the development of stereotactic body radiation therapy (SBRT) as an alternative treatment of extracranial oligometastases. New radiobiological concepts, such as ceramide-induced endothelial apoptosis after hypofractionated high-dose SBRT, and the identification of patients with oligometastatic disease by microRNA expression may yet lead to further developments. Key factors in SBRT are delivery of a high dose per fraction, proper patient positioning, target localisation, and management of breathing–related motion. Our review addresses the radiation doses and schedules used to treat liver, abdominal lymph node (LN) and adrenal gland oligometastases and treatment outcomes. Reported local control (LC) rates for liver and abdominal LN oligometastases are high (median 2-year actuarial LC: 61 -100% for liver oligometastases; 4-year actuarial LC: 68% in a study of abdominal LN oligometastases). Early toxicity is low-to-moderate; late adverse effects are rare. SBRT of adrenal gland oligometastases shows promising results in the case of isolated lesions. In conclusion, properly conducted SBRT procedures are a safe and effective treatment option for abdominal oligometastases.

show abstract

Section: Introductionmentioning

confidence: 99%